Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun 30;13(6):1056-1060.
doi: 10.21037/tau-24-7. Epub 2024 Jun 5.

Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer

Sia Viborg Lindskrog  1   2 , Lars Dyrskjøt  1   2
Affiliations
Editorial

Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer

Sia Viborg Lindskrog et al. Transl Androl Urol. .
No abstract available

Keywords: Circulating tumor DNA (ctDNA); adjuvant treatment; muscle-invasive bladder cancer (MIBC); urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-7/coif). L.D. has sponsored research agreements with Natera, C2i Genomics, AstraZeneca, Photocure, and Ferring, and has an advisory/consulting role at Ferring, MSD and UroGen. L.D. has received speaker honoraria from AstraZeneca, Pfizer and Roche and travel support from MSD. L.D. is a board member at BioXpedia. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Potential ctDNA-guided treatment of patients with MIBC. Schematic overview of a standard disease course for a patient with MIBC who have metastatic relapse after radical cystectomy. ctDNA and utDNA analyses may be used to guide neoadjuvant treatment and bladder preservation strategies. Plasma samples collected after radical cystectomy may be used to guide adjuvant treatment and for longitudinal disease surveillance. Plasma samples collected during treatment may inform on treatment response and treatments may be adapted accordingly. It is indicated in which settings clinical trials are currently going and where clinical trials are still needed. Blood and urine sample icons are from biorender.com. TURBT, transurethral resection of bladder tumor; ctDNA, circulating tumor DNA; utDNA, urinary tumor-derived DNA; RECIST, Response Evaluation Criteria in Solid Tumors; MIBC, muscle-invasive bladder cancer.
See this image and copyright information in PMC

Comment on

References

    1. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017;545:446-51. 10.1038/nature22364 - DOI - PMC - PubMed
    1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 2019;5:1124-31. 10.1001/jamaoncol.2019.0528 - DOI - PMC - PubMed
    1. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29:127-34. 10.1038/s41591-022-02115-4 - DOI - PMC - PubMed
    1. Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol 2019;37:1547-57. 10.1200/JCO.18.02052 - DOI - PubMed
    1. Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA 2018;4:FSO295. 10.4155/fsoa-2017-0140 - DOI - PMC - PubMed

LinkOut - more resources